Anika Therapeutics is a global joint preservation company that develops and commercializes hyaluronic acid-based injectable treatments for osteoarthritis pain management and regenerative orthopedic solutions. The company operates through two channels: an OEM manufacturing business supplying products to major partners like J&J MedTech under long-term agreements, and a commercial channel where the company directly controls sales, marketing, and pricing of regenerative solutions and international pain management products including Cingal, Integrity, Hyalofast, and Tactoset. Revenue is generated through both OEM manufacturing contracts and commercial direct sales across North American and international markets, with the company focused on early intervention orthopedics and expansion of its regenerative and international portfolios.